Compare Amgen, Inc. (AMGN) vs EPR Properties (EPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs EPR Properties — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while EPR Properties trades at $60 (market cap $4.56B). The key difference: Amgen, Inc. is far larger — about 43× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.24%). Which is the better fit depends on your goals.
| AMGN | EPR | |
|---|---|---|
Market Cap | $196.12B | $4.56B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $61.21 |
52-Week Low | $271.18 | $48.71 |
Enterprise Value | $241.41B | $7.62B |
Dividend Yield | 2.77% | 6.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EPR Properties trades at $59.62, up 0.08% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 39.93% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $315 million Six Flags acquisition and monthly dividends, reinforcing its experiential real estate focus.
Outlook remains positive with a consensus price target of $63.00, though risks include portfolio transition execution and sensitivity to consumer discretionary spending. The stock offers a 6%+ yield with solid coverage, appealing for income investors amid stable occupancy and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
